Sign In
Buy LPTX
$0.690
+0 (+0%)
At Close: Jun 23, 2026
Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis
01:14am, Tuesday, 03'rd Mar 2026
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and Panbela Therapeutics (OTCMKTS:PBLA - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will com
Leap Therapeutics (NASDAQ:LPTX) and Nemus Bioscience (OTCMKTS:NMUS) Critical Contrast
03:20am, Sunday, 11'th Jan 2026
Nemus Bioscience (OTCMKTS:NMUS - Get Free Report) and Leap Therapeutics (NASDAQ: LPTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the
Contrasting Leap Therapeutics (NASDAQ:LPTX) and UCB (OTCMKTS:UCBJF)
01:49am, Wednesday, 31'st Dec 2025
UCB (OTCMKTS:UCBJF - Get Free Report) and Leap Therapeutics (NASDAQ: LPTX - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based o
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC)
02:14am, Sunday, 28'th Dec 2025
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and Vincerx Pharma (NASDAQ: VINC - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contras
Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX)
03:42am, Thursday, 18'th Dec 2025
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and PaxMedica (NASDAQ: PXMD - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast the t
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
08:00am, Wednesday, 12'th Nov 2025
CAMBRIDGE, Mass. , Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients with cancer
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
07:00am, Wednesday, 12'th Nov 2025
Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
07:00am, Monday, 20'th Oct 2025
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to
CAMBRIDGE, Mass. , Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has cl
CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
07:00am, Thursday, 25'th Sep 2025
CAMBRIDGE, Mass. , Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it wi
Leap Therapeutics Reports Second Quarter 2025 Financial Results
07:00am, Thursday, 14'th Aug 2025
CAMBRIDGE, Mass. , Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia
Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated
Leap Therapeutics Reports First Quarter 2025 Financial Results
07:00am, Tuesday, 13'th May 2025
CAMBRIDGE, Mass. , May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
01:00pm, Friday, 25'th Apr 2025
FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE,
